ID   RD
AC   CVCL_1649
AS   CVCL_S332
SY   R D; RD-2; RD 2; 130T; 130-T; 130 T; TE-32; TE 32; TE32; TE 32.T; Te 32.T
DR   BTO; BTO:0005377
DR   CLO; CLO_0008693
DR   CLO; CLO_0008770
DR   EFO; EFO_0002315
DR   CLDB; cl4119
DR   CLDB; cl4120
DR   CLDB; cl4121
DR   CLDB; cl4122
DR   CLDB; cl4123
DR   CLDB; cl4124
DR   CLDB; cl4125
DR   CLDB; cl4126
DR   CLDB; cl4127
DR   AddexBio; C0035001/4950
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CCL-136
DR   ATCC; CRL-7713
DR   ATCC; CRL-7731
DR   ATCC; HTB-97
DR   BCRC; 60113
DR   BCRJ; 0260
DR   BioGRID_ORCS_Cell_line; 482
DR   BioSample; SAMN01821591
DR   BioSample; SAMN01821716
DR   BioSample; SAMN03472710
DR   BioSample; SAMN10988441
DR   cancercelllines; CVCL_1649
DR   CCRID; 1101HUM-PUMC000293
DR   CCRID; 1102HUM-NIFDC00079
DR   CCRID; 3101HUMTCHu45
DR   CCRID; 4201HUM-CCTCC00295
DR   CCTCC; GDC0295
DR   Cell_Model_Passport; SIDM00847
DR   ChEMBL-Cells; CHEMBL3307547
DR   ChEMBL-Targets; CHEMBL614144
DR   CLS; 300401
DR   Cosmic; 724833
DR   Cosmic; 801358
DR   Cosmic; 801760
DR   Cosmic; 802045
DR   Cosmic; 909264
DR   Cosmic; 1037298
DR   Cosmic; 1048111
DR   Cosmic; 1097753
DR   Cosmic; 1309330
DR   Cosmic; 1509195
DR   Cosmic; 1620036
DR   Cosmic; 1718099
DR   Cosmic; 2296987
DR   Cosmic; 2301590
DR   Cosmic; 2355912
DR   Cosmic-CLP; 909264
DR   DepMap; ACH-000169
DR   ECACC; 85111502
DR   EGA; EGAS00001000978
DR   GDSC; 909264
DR   GEO; GSM185149
DR   GEO; GSM186446
DR   GEO; GSM219726
DR   GEO; GSM887528
DR   GEO; GSM888610
DR   GEO; GSM1012752
DR   GEO; GSM1670368
DR   GEO; GSM1676309
DR   GEO; GSM1701643
DR   IARC_TP53; 767
DR   IGRhCellID; RD
DR   IZSLER; BS TCL 57
DR   JCRB; JCRB9072
DR   KCLB; 10136
DR   LiGeA; CCLE_882
DR   LINCS_LDP; LCL-1411
DR   Lonza; 1536
DR   PharmacoDB; RD_1296_2019
DR   PRIDE; PXD000589
DR   PRIDE; PXD007755
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1649
DR   PubChem_Cell_line; CVCL_1649
DR   TOKU-E; 2986
DR   Wikidata; Q54949532
RX   CelloPub=CLPUB00569;
RX   PubMed=77569;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=1917385;
RX   PubMed=2216456;
RX   PubMed=2302710;
RX   PubMed=3158613;
RX   PubMed=3518877;
RX   PubMed=4241949;
RX   PubMed=6220172;
RX   PubMed=7309287;
RX   PubMed=8275086;
RX   PubMed=8383879;
RX   PubMed=10899454;
RX   PubMed=12068308;
RX   PubMed=16518851;
RX   PubMed=17471488;
RX   PubMed=18082704;
RX   PubMed=19235922;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20922763;
RX   PubMed=21948088;
RX   PubMed=22142829;
RX   PubMed=22460905;
RX   PubMed=22541669;
RX   PubMed=23578105;
RX   PubMed=23828214;
RX   PubMed=23882450;
RX   PubMed=25894527;
RX   PubMed=26351324;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31448612;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   http://www.cccells.org/cellreqs-ncipptp.php
WW   http://www.pptpinvitro.org/cell_lines_panel.php
WW   https://en.vircell.com/products/rd-cell-line/
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 23 hours (PubMed=20922763).
CC   HLA typing: A*01; B*08,w15 (PubMed=77569).
CC   HLA typing: A*01:01,01:01; B*37:01,37:01; C*06:02,06:02; DQA1*04:01,04:01; DQB1*06:04,06:04; DRB1*10:01,13:05 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (PubMed=3158613; PubMed=12068308; PubMed=16518851; PubMed=22142829; ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (PubMed=2216456; ATCC; Cosmic-CLP; DepMap).
CC   Omics: Cell surface proteome.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Exosome proteome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=3.96%; Native American=0%; East Asian, North=4.77%; East Asian, South=0%; South Asian=0%; European, North=53.65%; European, South=37.61% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-7713; true.
CC   Discontinued: ATCC; CRL-7731; true.
CC   Discontinued: ATCC; HTB-97; true.
CC   Derived from site: In situ; Pelvis, muscle; UBERON=UBERON_0001325.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; COG; ECACC; JCRB; KCLB; PubMed=20922763; PubMed=21948088
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 13
ST   D16S539: 10,11
ST   D18S51: 13,18
ST   D19S433: 11,14
ST   D21S11: 28,29
ST   D2S1338: 17,23
ST   D3S1358: 15,17
ST   D5S818: 11
ST   D7S820: 8,12
ST   D8S1179: 11,15
ST   FGA: 20,21
ST   Penta D: 11,13
ST   Penta E: 12
ST   TH01: 9.3
ST   TPOX: 9
ST   vWA: 18
DI   NCIt; C8971; Embryonal rhabdomyosarcoma
DI   ORDO; Orphanet_99757; Embryonal rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   7Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 46
//
RX   CelloPub=CLPUB00569;
RA   Dickman P.S., Tsokos M.G., Triche T.J.;
RT   "Biology of rhabdomyosarcoma: cell culture, xenografts, and animal
RT   models.";
RL   (In) Rhabdomyosarcoma and related tumors in children and adolescents; Maurer H.M., Ruymann F.B., Pochedly C.E. (eds.); pp.49-88; CRC Press; Boca Raton (1991).
//
RX   PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x;
RA   Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.;
RT   "Tissue typing of cells in culture. III. HLA antigens of established
RT   human cell lines. Attempts at typing by the mixed hemadsorption
RT   technique.";
RL   Tissue Antigens 11:279-286(1978).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=1917385;
RA   Lollini P.-L., De Giovanni C., Landuzzi L., Nicoletti G., Scotlandi K.,
RA   Nanni P.;
RT   "Reduced metastatic ability of in vitro differentiated human
RT   rhabdomyosarcoma cells.";
RL   Invasion Metastasis 11:116-124(1991).
//
RX   PubMed=2216456;
RA   Stratton M.R., Moss S., Warren W., Patterson H., Clark J., Fisher C.,
RA   Fletcher C.D.M., Ball A., Thomas M., Gusterson B.A., Cooper C.S.;
RT   "Mutation of the p53 gene in human soft tissue sarcomas: association
RT   with abnormalities of the RB1 gene.";
RL   Oncogene 5:1297-1301(1990).
//
RX   PubMed=2302710;
RA   Ozkaynak M.F., Nolta J., Parkman R.;
RT   "In vitro purging of human rhabdomyosarcoma cells using
RT   4-hydroperoxycyclophosphamide.";
RL   Cancer Res. 50:1455-1458(1990).
//
RX   PubMed=3158613; DOI=10.1002/ijc.2910350513;
RA   Chardin P., Yeramian P.D., Madaule P., Tavitian A.;
RT   "N-ras gene activation in the RD human rhabdomyosarcoma cell line.";
RL   Int. J. Cancer 35:647-652(1985).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=4241949; DOI=10.1002/1097-0142(196909)24:3<520::AID-CNCR2820240313>3.0.CO;2-M;
RA   McAllister R.M., Melnyk J., Finkelstein J.Z., Adams E.C. Jr.,
RA   Gardner M.B.;
RT   "Cultivation in vitro of cells derived from a human
RT   rhabdomyosarcoma.";
RL   Cancer 24:520-526(1969).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=7309287; DOI=10.1002/ijc.2910280403;
RA   Houghton J.A., Houghton P.J., Brodeur G.M., Green A.A.;
RT   "Development of resistance to vincristine in a childhood
RT   rhabdomyosarcoma growing in immune-deprived mice.";
RL   Int. J. Cancer 28:409-415(1981).
//
RX   PubMed=8275086; DOI=10.1038/ng1193-230;
RA   Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S.,
RA   Rauscher F.J. III, Emanuel B.S., Rovera G., Barr F.G.;
RT   "Fusion of a fork head domain gene to PAX3 in the solid tumour
RT   alveolar rhabdomyosarcoma.";
RL   Nat. Genet. 5:230-235(1993).
//
RX   PubMed=8383879; DOI=10.1126/science.8383879;
RA   Tapscott S.J., Thayer M.J., Weintraub H.M.;
RT   "Deficiency in rhabdomyosarcomas of a factor required for MyoD
RT   activity and myogenesis.";
RL   Science 259:1450-1453(1993).
//
RX   PubMed=10899454; DOI=10.1016/s0960-8966(00)00096-1;
RA   Vergani L., Prescott A.R., Holt I.J.;
RT   "Rhabdomyosarcoma rho(0) cells: isolation and characterization of a
RT   mitochondrial DNA depleted cell line with 'muscle-like' properties.";
RL   Neuromuscul. Disord. 10:454-459(2000).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=16518851; DOI=10.1002/gcc.20322;
RA   Chen Y.-Y., Takita J., Hiwatari M., Igarashi T., Hanada R., Kikuchi A.,
RA   Hongo T., Taki T., Ogasawara M., Shimada A., Hayashi Y.;
RT   "Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and
RT   pediatric hematological malignancies.";
RL   Genes Chromosomes Cancer 45:583-591(2006).
//
RX   PubMed=17471488; DOI=10.1002/path.2170;
RA   Lae M., Ahn E.H., Mercado G.E., Chuai S., Edgar M., Pawel B.R.,
RA   Olshen A., Barr F.G., Ladanyi M.;
RT   "Global gene expression profiling of PAX-FKHR fusion-positive alveolar
RT   and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.";
RL   J. Pathol. 212:143-151(2007).
//
RX   PubMed=18082704; DOI=10.1016/j.jpedsurg.2007.08.026;
RA   Komuro H., Saihara R., Shinya M., Takita J., Kaneko S., Kaneko M.,
RA   Hayashi Y.;
RT   "Identification of side population cells (stem-like cell population)
RT   in pediatric solid tumor cell lines.";
RL   J. Pediatr. Surg. 42:2040-2045(2007).
//
RX   PubMed=19235922; DOI=10.1002/gcc.20655;
RA   Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C.,
RA   Koster J., Summersgill B.M., Messahel B., Versteeg R.,
RA   Pritchard-Jones K., Kool M., Shipley J.M.;
RT   "Genomic imbalances in rhabdomyosarcoma cell lines affect expression
RT   of genes frequently altered in primary tumors: an approach to identify
RT   candidate genes involved in tumor development.";
RL   Genes Chromosomes Cancer 48:455-467(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=21948088; DOI=10.1158/1078-0432.CCR-11-1004;
RA   Belyea B.C., Naini S., Bentley R.C., Linardic C.M.;
RT   "Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma
RT   tumorigenesis.";
RL   Clin. Cancer Res. 17:7324-7336(2011).
//
RX   PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056;
RA   Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A.,
RA   Borsu L., Barr F.G., Ladanyi M.;
RT   "Oncogene mutation profiling of pediatric solid tumors reveals
RT   significant subsets of embryonal rhabdomyosarcoma and neuroblastoma
RT   with mutated genes in growth signaling pathways.";
RL   Clin. Cancer Res. 18:748-757(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22541669; DOI=10.1186/2044-5040-2-7;
RA   MacQuarrie K.L., Yao Z.-Z., Young J.M., Cao Y., Tapscott S.J.;
RT   "miR-206 integrates multiple components of differentiation pathways to
RT   control the transition from growth to differentiation in
RT   rhabdomyosarcoma cells.";
RL   Skelet. Muscle 2:7.1-7.14(2012).
//
RX   PubMed=23578105; DOI=10.1111/cas.12173;
RA   Nishimura R., Takita J., Sato-Otsubo A., Kato M., Koh K., Hanada R.,
RA   Tanaka Y., Kato K., Maeda D., Fukayama M., Sanada M., Hayashi Y.,
RA   Ogawa S.;
RT   "Characterization of genetic lesions in rhabdomyosarcoma using a
RT   high-density single nucleotide polymorphism array.";
RL   Cancer Sci. 104:856-864(2013).
//
RX   PubMed=23828214; DOI=10.3892/or.2013.2588;
RA   Yamamoto Y., Fukuda K., Fuchimoto Y., Matsuzaki Y., Saikawa Y.,
RA   Kitagawa Y., Morikawa Y., Kuroda T.;
RT   "Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with
RT   EGFR amplification in vitro.";
RL   Oncol. Rep. 30:1081-1086(2013).
//
RX   PubMed=23882450; DOI=10.3389/fonc.2013.00183;
RA   Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G.,
RA   Linardic C.M.;
RT   "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research:
RT   utility and pitfalls.";
RL   Front. Oncol. 3:183.1-183.12(2013).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31448612; DOI=10.1021/acs.jproteome.9b00157;
RA   Rammal G., Fahs A., Kobeissy F., Mechref Y., Zhao J.-F., Zhu R.,
RA   Diab-Assaf M., Saab R., Ghayad S.E.;
RT   "Proteomic profiling of rhabdomyosarcoma-derived exosomes yield
RT   insights into their functional role in paracrine signaling.";
RL   J. Proteome Res. 18:3567-3579(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//